Publications

November, 2024

Dihydroergotamine for migraine: Evidence for multiple modes of action: The single molecule ‘combination’ product—A narrative review

Stewart J. Tepper, MD; Detlef Albrecht, MD; Don Kellerman, PharmD

Published in Cephalalgia Reports. 2024; 7: 1-11

View Publication

October, 2024

Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study

Stewart J. Tepper, MD; Detlef Albrecht, MD; Jessica Ailani, MD; Louis Kirby, MD; Shannon Strom, PhD; Alan M. Rapoport, MD

Published in CNS Drugs 07 October, 2024

View Publication

June, 2024

Long-Term Safety and Tolerability Data of STS101 From the Phase 3 Open-Label ASCEND Study

Stewart J. Tepper, MD; Amaal J. Starling, MD; Shannon Strom, PhD; Detlef Albrecht, MD

Presented at the American Headache Society (AHS) Annual Meeting, 2024

View Publication

June, 2024

STS101 Demonstrated Long-Term Clinical Benefit in the Phase 3 Open-Label ASCEND Study

Larry Charleston IV, MD, MSc, FAHS; Shannon Strom, PhD; Detlef Albrecht, MD; Robert P. Cowan, MD

Presented at the American Headache Society (AHS) Annual Meeting, 2024

View Publication

June, 2024

STS101 (Dihydroergotamine Nasal Powder) Shows Long Duration Anti-Migraine Benefit on Baseline Photophobia,Phonophobia, and Nausea: Results From the Phase 3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study

Christopher Gottschalk, MD; Egilius L.H. Spierings, MD; Shannon Strom, PhD; Detlef Albrecht, MD

Presented at the American Headache Society (AHS) Annual Meeting, 2024

View Publication

June, 2024

STS101 (Dihydroergotamine Nasal Powder) Shows Pain Relief in Difficult to Treat Migraine Attacks: Results From the Phase 3 Double-blind, Randomized, Placebo-controlled SUMMIT Study

Jessica Ailani, MD; Shannon Strom, PhD; Detlef Albrecht, MD; Alan Rapoport, MD

Presented at the American Headache Society (AHS) Annual Meeting, 2024

View Publication

June, 2024

Subjects View Use of STS101 Favorably: Subject Impression Data From the Phase 3 Open-Label ASCEND Study

Jessica Ailani, MD; Shannon Strom, PhD; Detlef Albrecht, MD; Alan Rapoport, MD

Presented at the American Headache Society (AHS) 2024 Annual Meeting

View Publication

February, 2024

A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults

Richard B. Lipton, MD; Detlef Albrecht, MD; Maria Bermudez, MD; Jerry Hu, PharmD; Elizabeth Hussey, PharmD; Jeff Levy, MD

Headache. 2024;00:1–10

View Publication

June, 2023

Efficacy of STS101 DHE Nasal Powder for the Acute Treatment of Difficult to Treat Migraines: Results from the Phase 3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study

Jessica Ailani, MD; Detlef Albrecht, MD; and Robert Cowan, MD

Presented at the American Headache Society (AHS) Annual Meeting, June 15‒18, 2023, Austin, TX.

View Publication

June, 2023

Efficacy and Safety of STS101 DHE Nasal Powder for the Acute Treatment of Migraine: Results from the Phase 3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study

Richard B. Lipton, MD; Stewart Tepper, MD; Detlef Albrecht, MD

Presented at the American Headache Society (AHS) Annual Meeting, June 15‒18, 2023, Austin, TX.

View Publication

May, 2023

Interim Analysis of STS101 Nasal Safety Data From the Phase 3 Open-Label ASCEND Migraine Study

Egilius L.H. Spierings, MD; Detlef Albrecht, MD and Alan M. Rapoport, MD

Presented at the Annual Meeting of the American Academy of Neurology (AAN) 2023

View Publication

May, 2023

Interim Analysis of Subject Impression Data for STS101 From the Phase 3 Open-Label ASCEND Study 

Jessica Ailani, MD; Larry Charleston IV, MD; Detlef Albrecht, MD

Presented at the Annual Meeting of the American Academy of Neurology (AAN) 2023

View Publication

May, 2023

Interim Analysis of Long-Term Safety and Tolerability Data of STS101 From the Phase 3 Open-Label
ASCEND Study

Stewart J. Tepper, MD; Amaal J. Starling, MD and Detlef Albrecht, MD

Presented at the Annual Meeting of the American Academy of Neurology (AAN) 2023

View Publication

June, 2022

Subject Impression Data for STS101 From the Ongoing Phase 3 Open-Label ASCEND Study 

Jessica Ailani, MD; Shannon Strom, PhD; John Kollins; and Detlef Albrecht, MD

Presented at the American Headache Society (AHS) Annual Meeting 2022

View Publication

June, 2022

Nasal Safety Data of STS101 From the Ongoing Phase 3 Open-Label ASCEND Study 

Alan M. Rapoport, MD; Shannon Strom, PhD; Detlef Albrecht, MD

Presented at the American Headache Society (AHS) Annual Meeting 2022

View Publication

June, 2022

STS101 Demonstrates Rapid, Consistent Absorption and Sustained Target Plasma Concentrations of Dihydroergotamine (DHE) With Low Variability 

Egilius L.H. Spierings, MD; Shannon Strom, PhD; Detlef Albrecht, MD

American Headache Society (AHS) Annual Meeting 2022

View Publication

June, 2022

Relationship of Dihydroergotamine (DHE) Pharmacokinetic Parameters and Clinical Efficacy and Systemic Side Effects 

John Kollins, BSE, MBA; Shannon Strom, PhD; and Detlef Albrecht, MD

American Headache Society (AHS) Annual Meeting 2022

View Publication

April, 2022

Long-term safety and tolerability of STS101, a novel investigational dihydroergotamine nasal powder: initial data from the ASCEND study 

Stewart J. Tepper, MD, Shannon Strom, PhD, Detlef Albrecht, MD

American Academy of Neurology 2022 Annual Meeting

View Publication

April, 2022

Cardiovascular safety of STS101, a novel investigational DHE nasal powder product: initial data from the ASCEND study 

Alan Rapoport, MD, Shannon Strom, PhD, Detlef Albrecht, MD

American Academy of Neurology 2022 Annual Meeting

View Publication

April, 2022

Pharmacokinetics and safety of STS101, a novel investigational DHE powder drug-device combination in healthy subjects 

Detlef Albrecht, MD, Richard B. Lipton, MD, Shannon Strom, PhD

American Academy of Neurology 2022 Annual Meeting

View Publication

April, 2022

Pharmacokinetic comparison of STS101 (A novel investigational DHE nasal powder) with liquid nasal spray, injectable, and oral inhaled DHE formulations 

Shannon Strom, PhD, Detlef Albrecht

American Academy of Neurology 2022 Annual Meeting

View Publication

June, 2020

The Efficacy of Dihydroergotamine versus Emerging Acute Migraine Medications

Shannon Strom, PhD; John Kollins; Detlef Albrecht, MD (2020)

Presented June 2020 (virtually) at the American Headache Society’s Annual Scientific Meeting

View Publication

June, 2020

Safety of Dihydroergotamine for the Acute Treatment of Migraine: Reality vs Perception

Alan M Rapoport, MD; Shannon Strom, PhD; Detlef Albrecht, MD; John Kollins (2020)

Presented June 2020 (virtually) at the American Headache Society's Annual Scientific Meeting

View Publication

May, 2020

Water-insoluble Mucoadhesive Formulation Enables Consistent and Rapid Intranasal Absorption of Drugs, including Granisetron, Zolmitriptan and Dihydroergotamine

Mic Iwashima (2020).

American Academy of Neurology 2020 Annual Meeting

View Publication

May, 2020

Pharmacokinetic comparison of STS101, an intranasal dry powder formulation of dihydroergotamine, with other intranasal, injectable and oral inhaled DHE formulations

Shannon Strom, PhD; John Kollins; Detlef Albrecht, MD (2020)

American Academy of Neurology 2020 Annual Meeting

View Publication

January, 2020

A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects

Detlef Albrecht, MD; Mic Iwashima; Debbie Dillon; Stuart Harris, MD; Jeff Levy, MD (2020).

Headache 2020;0:1-12

View Publication

September, 2019

Comparison of the Pharmacokinetics of STS101, an Intranasal Dry Powder Formulation of Dihydroergotamine, with Other Intranasal, Injectable, and Oral Inhaled DHE Formulations

Strom, S., Kollins, J., Albrecht D. (2019).

Presented September 2019 at IHC 2019, the 19th Congress of the International Headache Society.

View Publication

September, 2019

STS101 (Dry Powder Intranasal Dihydroergotamine) Drug-Device Combination Achieves Consistent and Robust Delivery Performance for Migraine Patients

Iwashima, M., Schultz, R.D. (2019).

Presented September 2019 at IHC 2019, the 19th Congress of the International Headache Society.

View Publication

July, 2019

Pharmacokinetics and Safety of Intranasal Dihydroergotamine Powder (STS101).

Albrecht, D., Iwashima, M., Dillon, D., Harris, S., Levy, S. (2019).

Presented July 2019 at the American Headache Society's 61st Annual Scientific Meeting.

View Publication